{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:45:49Z","timestamp":1793180749153,"version":"4.5.0"},"reference-count":108,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/hco.0b013e32832ebfe7","type":"journal-article","created":{"date-parts":[[2009,8,3]],"date-time":"2009-08-03T09:01:11Z","timestamp":1249290071000},"page":"473-482","source":"Crossref","is-referenced-by-count":25,"title":["Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels"],"prefix":"10.1097","volume":"24","author":[{"given":"Derek J","family":"Hausenloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek M","family":"Yellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210204","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R2-14-20210204","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-14-20210204","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-14-20210204","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"R5-14-20210204","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"R6-14-20210204","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.ATV.8.6.737","article-title":"High density lipoprotein cholesterol and mortality. The Framingham Heart Study","volume":"8","author":"Wilson","year":"1988","journal-title":"Arteriosclerosis"},{"key":"R7-14-20210204","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"issue":"Suppl","key":"R8-14-20210204","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","article-title":"High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport","volume":"124","author":"Assmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"R9-14-20210204","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.ATV.17.1.107","article-title":"Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men","volume":"17","author":"Goldbourt","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R10-14-20210204","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1185\/030079905X74871","article-title":"High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients","volume":"21","author":"Bruckert","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R11-14-20210204","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"R12-14-20210204","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1172\/JCI30163","article-title":"Molecular regulation of HDL metabolism and function: implications for novel therapies","volume":"116","author":"Rader","year":"2006","journal-title":"J Clin Invest"},{"key":"R13-14-20210204","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.pharmthera.2006.02.003","article-title":"Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease","volume":"111","author":"Chapman","year":"2006","journal-title":"Pharmacol Ther"},{"key":"R14-14-20210204","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/hrt.2007.125401","article-title":"Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels","volume":"94","author":"Hausenloy","year":"2008","journal-title":"Heart"},{"key":"R15-14-20210204","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"R16-14-20210204","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R17-14-20210204","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R18-14-20210204","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R19-14-20210204","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"},{"key":"R20-14-20210204","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ahj.2003.10.033","article-title":"Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study","volume":"147","author":"Ellison","year":"2004","journal-title":"Am Heart J"},{"key":"R21-14-20210204","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1161\/01.CIR.91.10.2596","article-title":"Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years","volume":"91","author":"King","year":"1995","journal-title":"Circulation"},{"key":"R22-14-20210204","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1001\/jama.1987.03400170074026","article-title":"Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial","volume":"258","author":"Leon","year":"1987","journal-title":"JAMA"},{"key":"R23-14-20210204","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.1989.03430170057028","article-title":"Physical fitness and all-cause mortality. A prospective study of healthy men and women","volume":"262","author":"Blair","year":"1989","journal-title":"JAMA"},{"key":"R24-14-20210204","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.81.4.1428","article-title":"What do muscles have to do with lipoproteins?","volume":"81","author":"Thompson","year":"1990","journal-title":"Circulation"},{"key":"R25-14-20210204","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-7435(03)00110-5","article-title":"The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis","volume":"37","author":"Maeda","year":"2003","journal-title":"Prev Med"},{"key":"R26-14-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0021-9150(78)90149-1","article-title":"Cigarette smoking and HDL cholesterol: the Framingham offspring study","volume":"30","author":"Garrison","year":"1978","journal-title":"Atherosclerosis"},{"key":"R27-14-20210204","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"key":"R28-14-20210204","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"R29-14-20210204","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/07315724.2004.10719353","article-title":"Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women","volume":"23","author":"Meksawan","year":"2004","journal-title":"J Am Coll Nutr"},{"key":"R30-14-20210204","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/154099903321576493","article-title":"Dietary fat and cardiovascular disease risk: quantity or quality?","volume":"12","author":"Lichtenstein","year":"2003","journal-title":"J Womens Health (Larchmt)"},{"key":"R31-14-20210204","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J Intern Med"},{"key":"R32-14-20210204","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1742-1241.2007.01514.x","article-title":"Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan)","volume":"61","author":"Vogt","year":"2007","journal-title":"Int J Clin Pract"},{"key":"R33-14-20210204","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/S0140-6736(04)16359-9","article-title":"The nicotinic acid receptor: a new mechanism for an old drug","volume":"363","author":"Karpe","year":"2004","journal-title":"Lancet"},{"key":"R34-14-20210204","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bcp.2003.09.014","article-title":"Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin","volume":"67","author":"Rubic","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R35-14-20210204","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.17.10.2020","article-title":"Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport","volume":"17","author":"Jin","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R36-14-20210204","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R37-14-20210204","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R38-14-20210204","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"R39-14-20210204","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2008.584","article-title":"Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial","volume":"169","author":"Goldenberg","year":"2009","journal-title":"Arch Intern Med"},{"key":"R40-14-20210204","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"R41-14-20210204","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"R42-14-20210204","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R43-14-20210204","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-128-4-199802150-00002","article-title":"The role of carotid arterial intima-media thickness in predicting clinical coronary events","volume":"128","author":"Hodis","year":"1998","journal-title":"Ann Intern Med"},{"key":"R44-14-20210204","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00129784-200808020-00001","article-title":"Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study","volume":"8","author":"Karas","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"R45-14-20210204","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","article-title":"Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)","volume":"101","author":"Ballantyne","year":"2008","journal-title":"Am J Cardiol"},{"key":"R46-14-20210204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R47-14-20210204","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/030079906X89766","article-title":"Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study","volume":"22","author":"Vogt","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R48-14-20210204","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R49-14-20210204","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Benyo","year":"2005","journal-title":"J Clin Invest"},{"key":"R50-14-20210204","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R51-14-20210204","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"R52-14-20210204","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1592\/phco.27.3.412","article-title":"Fibrates: what have we learned in the past 40 years?","volume":"27","author":"Backes","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R53-14-20210204","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1172\/JCI111879","article-title":"Mechanism of action of gemfibrozil on lipoprotein metabolism","volume":"75","author":"Saku","year":"1985","journal-title":"J Clin Invest"},{"key":"R54-14-20210204","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"R55-14-20210204","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jama.297.12.1362","article-title":"Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials","volume":"297","author":"Nissen","year":"2007","journal-title":"JAMA"},{"key":"R56-14-20210204","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.amjcard.2008.03.076","article-title":"Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus","volume":"102","author":"Terra","year":"2008","journal-title":"Am J Cardiol"},{"key":"R57-14-20210204","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/archinte.164.19.2097","article-title":"A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors","volume":"164","author":"Chiquette","year":"2004","journal-title":"Arch Intern Med"},{"key":"R58-14-20210204","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/01.ATV.0000195790.24531.4f","article-title":"Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome","volume":"26","author":"Szapary","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R59-14-20210204","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"R60-14-20210204","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R61-14-20210204","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.2337\/diacare.27.6.1324","article-title":"Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm","volume":"27","author":"Saad","year":"2004","journal-title":"Diabetes Care"},{"key":"R62-14-20210204","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"R63-14-20210204","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1185\/030079906X154169","article-title":"Effect of tesaglitazar, a dual PPAR alpha\/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial","volume":"22","author":"Goldstein","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R64-14-20210204","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9150(99)00053-2","article-title":"Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease","volume":"144","author":"Schaefer","year":"1999","journal-title":"Atherosclerosis"},{"key":"R65-14-20210204","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11883-002-0065-8","article-title":"Gut-acting drugs for lowering cholesterol","volume":"4","author":"Black","year":"2002","journal-title":"Curr Atheroscler Rep"},{"key":"R66-14-20210204","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0021-9150(01)00705-5","article-title":"Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage","volume":"162","author":"Kobayashi","year":"2002","journal-title":"Atherosclerosis"},{"key":"R67-14-20210204","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R68-14-20210204","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"R69-14-20210204","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R70-14-20210204","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels","volume":"48","author":"Davidson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R71-14-20210204","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"R72-14-20210204","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"R73-14-20210204","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R74-14-20210204","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1161\/CIRCULATIONAHA.108.772665","article-title":"Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials","volume":"118","author":"Vergeer","year":"2008","journal-title":"Circulation"},{"key":"R75-14-20210204","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R76-14-20210204","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein (CETP) inhibition","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"key":"R77-14-20210204","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"key":"R78-14-20210204","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"R79-14-20210204","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"de Grooth","year":"2002","journal-title":"Circulation"},{"key":"R80-14-20210204","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjcard.2004.12.064","article-title":"Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia","volume":"95","author":"Kuivenhoven","year":"2005","journal-title":"Am J Cardiol"},{"key":"R81-14-20210204","first-page":"S452","article-title":"No increase in the in vitro production of aldosterone or the expression of CYP11B2 with the CETP modulator dalcetrapib (RO4607381\/JTT-705), in contrast with torcetrapib [abstract]","volume":"118","author":"Capponi","year":"2008","journal-title":"Circulation"},{"key":"R82-14-20210204","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J Clin Invest"},{"key":"R83-14-20210204","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1172\/JCI109956","article-title":"A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family","volume":"66","author":"Franceschini","year":"1980","journal-title":"J Clin Invest"},{"key":"R84-14-20210204","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"R85-14-20210204","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/HCO.0b013e3283007ccd","article-title":"Acute effects of high-density lipoproteins: biochemical basis and clinical findings","volume":"23","author":"Chiesa","year":"2008","journal-title":"Curr Opin Cardiol"},{"key":"R86-14-20210204","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"R87-14-20210204","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-2275(20)31163-9","article-title":"A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis","volume":"42","author":"Garber","year":"2001","journal-title":"J Lipid Res"},{"key":"R88-14-20210204","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","article-title":"Oral D-4F causes formation of prebeta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice","volume":"109","author":"Navab","year":"2004","journal-title":"Circulation"},{"key":"R89-14-20210204","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"R90-14-20210204","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","article-title":"Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients","volume":"49","author":"Bloedon","year":"2008","journal-title":"J Lipid Res"},{"key":"R91-14-20210204","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1194\/jlr.M200475-JLR200","article-title":"Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway","volume":"44","author":"Remaley","year":"2003","journal-title":"J Lipid Res"},{"key":"R92-14-20210204","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1124\/jpet.107.129411","article-title":"Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides","volume":"324","author":"Gomaraschi","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R93-14-20210204","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/01.CIR.0000089375.60050.35","article-title":"Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice","volume":"108","author":"Navab","year":"2003","journal-title":"Circulation"},{"key":"R94-14-20210204","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1194\/jlr.M400438-JLR200","article-title":"Phosphatidylinositol increases HDL-C levels in humans","volume":"46","author":"Burgess","year":"2005","journal-title":"J Lipid Res"},{"key":"R95-14-20210204","doi-asserted-by":"crossref","first-page":"n15","DOI":"10.1016\/j.amjcard.2007.08.008","article-title":"Liver X receptor and farnesoid X receptor as therapeutic targets","volume":"100","author":"Rader","year":"2007","journal-title":"Am J Cardiol"},{"key":"R96-14-20210204","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1073\/pnas.112059299","article-title":"Synthetic LXR ligand inhibits the development of atherosclerosis in mice","volume":"99","author":"Joseph","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R97-14-20210204","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(02)03578-0","article-title":"T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice","volume":"536","author":"Terasaka","year":"2003","journal-title":"FEBS Lett"},{"key":"R98-14-20210204","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.ATV.0000150044.84012.68","article-title":"Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists","volume":"25","author":"Levin","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R99-14-20210204","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.105.560177","article-title":"Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo","volume":"113","author":"Naik","year":"2006","journal-title":"Circulation"},{"key":"R100-14-20210204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.febslet.2007.11.015","article-title":"FXR signaling in metabolic disease","volume":"582","author":"Zhang","year":"2008","journal-title":"FEBS Lett"},{"key":"R101-14-20210204","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2174\/138955708784534427","article-title":"Endothelial Lipase: a key player in HDL metabolism modulates inflammation and atherosclerotic risk","volume":"8","author":"DeSantis","year":"2008","journal-title":"Mini Rev Med Chem"},{"key":"R102-14-20210204","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/7766","article-title":"A novel endothelial-derived lipase that modulates HDL metabolism","volume":"21","author":"Jaye","year":"1999","journal-title":"Nat Genet"},{"key":"R103-14-20210204","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1172\/JCI16306","article-title":"Endothelial lipase is a major determinant of HDL level","volume":"111","author":"Ishida","year":"2003","journal-title":"J Clin Invest"},{"key":"R104-14-20210204","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1073\/pnas.0438039100","article-title":"Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism","volume":"100","author":"Ma","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R105-14-20210204","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1172\/JCI16146","article-title":"Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo","volume":"111","author":"Jin","year":"2003","journal-title":"J Clin Invest"},{"key":"R106-14-20210204","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1371\/journal.pmed.0030022","article-title":"Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis","volume":"3","author":"Badellino","year":"2006","journal-title":"PLoS Med"},{"key":"R107-14-20210204","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.107.707349","article-title":"Endothelial lipase is increased in vivo by inflammation in humans","volume":"117","author":"Badellino","year":"2008","journal-title":"Circulation"},{"key":"R108-14-20210204","first-page":"1042","article-title":"Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans","volume":"119","author":"Edmondson","year":"2009","journal-title":"J Clin Invest"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HCO.0b013e32832ebfe7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:51:16Z","timestamp":1620953476000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001573-200909000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0b013e32832ebfe7","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}